Microsoft’s Windows 8 Resilient to Piracy and 2 Dow Movers to Follow

Merck & Co. (NYSE:MRK) and Ariad Pharmaceuticals (NASDAQ:ARIA) are co-developing Jenzyl which is a trade name for ridaforolimus, a maintenance treatment of patients with metastatic soft tissue sarcoma or bone sarcoma previously treated with chemotherapy, and was expected to be used for the treatment of adults suffering from soft tissue sarcoma, a type of cancer that affects the soft, supporting tissues of the body, or bone sarcoma that has spread to other parts of the body. The European Medicines Agency reported that on November 27th, Merck Sharp & Dohme officially notified the Committee for Medicinal Products for Human Use, or CHMP, of the withdrawal of its application for a marketing authorization for Jenzyl after the CHMP had evaluated the documentation supplied by the company and formulated a list of questions, to which the firm had not yet responded to the last round. Subsequent to the review of the data and the company’s response to the CHMP list of questions at the time of the withdrawal, the CHMP had some worries and had the provisional opinion that Jenzyl could not have been approved for the treatment of patients with metastatic soft tissue sarcoma or bone sarcoma as maintenance therapy.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now >>

Microsoft Corporation’s (NASDAQ:MSFT) new Windows 8 is giving software pirates in China an operating system that is the most resilient to piracy that the company thus far has released, says the Wall Street Journal. Vice President Nick Psyhogeos commented that, “We are aware though that software pirates are smart and they have a way to react and respond to any technological advancement we might introduce.” Microsoft is appealing to consumers in order to educate them regarding the dangers of purchasing computers that have unlicensed versions of Windows installed.

The Boeing Company’s (NYSE:BA) order of ten new Boeing  737-800 aircraft by AerCap Holdings (NYSE:AER) will be financed by a $200 million facility with DBS Bank of Singapore for pre-delivery payments. This funding facility concludes all of AerCap’s pre-delivery payment requirements for its order which was placed in 2010 with deliveries scheduled during 2015.

Don’t Miss: Can Apple Fix Its China Problem?